Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7412320 | 0.84 | HTT (0.43) | LMNAHSD17B10CA1CA2NPC1 | |
| SCHEMBL5655847 | 0.83 | PTGDR2 (0.38) | LMNAL3MBTL1HSD17B10ALDH1A1MAPT | |
| SCHEMBL5655590 | 0.79 | CA12 (0.43) | LMNAL3MBTL1CA12CA1CA2 | |
| SCHEMBL26677157 | 0.77 | PARP15 (0.46) | HSD17B10 | |
| SCHEMBL26677151 | 0.77 | PARP15 (0.46) | HSD17B10 | |
| SCHEMBL2219445 | 0.77 | AKR1C3 (0.46) | LMNANPC1ALDH1A1MAPTMEN1 | |
| SCHEMBL2219452 | 0.77 | AKR1C3 (0.46) | LMNANPC1ALDH1A1MAPTMEN1 | |
| SCHEMBL6117811 | 0.76 | HSD17B10 (0.39) | HSD17B10ALDH1A1MEN1KMT2AKEAP1 | |
| SCHEMBL2117365 | 0.75 | SMN1; SMN2 (0.47) | CA1CA2NPC1ALDH1A1MAPT | |
| SCHEMBL17854031 | 0.75 | CA12 (0.50) | LMNAL3MBTL1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563765-B1 | BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. | TAKEDA PHARMACEUTICAL (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-8703758-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20110263562-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263562-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | LMNA 1054/4885L3MBTL1 1235/4885HSD17B10 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.